Biocon Ltd. — Interim / Quarterly Report 2020

Jun 11, 2020

==> picture [149 x 53] intentionally omitted <==

==> picture [453 x 94] intentionally omitted <==

==> picture [63 x 30] intentionally omitted <==

==> picture [81 x 79] intentionally omitted <==

Nameofrelatedparties	Natureofrelationship
Key management personnel/Directors
Kiran Mazumdar-Shaw	Chairperson&Managing Director#
Arun Chandavarkar	Joint Managing Director&CEO(w.e.f April24,2014,upto November 30, 2019)
Siddharth Mittal	Joint ManagingDirector&CEO(effectivefromDecember1,2019) #
SiddharthMittal	President - Finance&Chief Financial Officer (upto November 30, 2019)
Mayank Verma	Company Secretary (w.e.f July25, 2019)
Russell Walls	Independent director (upto July26,2019)
Daniel M Bradbury	Independent director
Jeremy M Levin	Independent director (upto January 23, 2020)
MaryHarney	Independent director
Vijay K Kuchroo	Independent director
M Damodaran	Independent director
Bobby K Parikh	Independent director
John Shaw	Non-executive director
RaviMazumdar	Non-executive director
JointVentures
NeoBioconFZLLC	Joint-venture
Other related parties
Biocon Foundation	Trust in which key management personnel aretheBoardofTrustees
lmmuneel Therapeutics Private Limited	Enterprise in which a directoroftheCompanyisa shareholder
Mazumdar Shaw Medical Foundation	Trust in which key management personnel are the BoardofTrustees
Glentec International Limited	Enterprise ownedbykey management personnel
Catherine Rosenberg	Relativeofa director
Clarie Mazumdar	Relativeofa director
Jeeves	Enterprise in which relativetoa directoroftheCompanyisproprietor
Narayana Hrudayalaya Limited	Enterprise in which a directoroftheCompanyisa memberofboardofdirectors

The Grouphasthefollowingrelatedpartytransactions
		Half year ended
Particulars	Transactions/Balances	March 31, 2020
Keymanagementpersonnel/Directors	Salary and perquisites [refer note(a)&(b) below]	65
	Sitting fees and commission	18
	Outstandingasattheperiod end:
	- Trade andotherpayables	2
JointVenture	Purchaseofgoods	502
	Sales promotion expenses	122
	Expenses incurredonbehalfofthe related party	3
	Outstandingasatthe period end:
	- Trade andotherreceivables	5
	- Trade andotherpayables	428
Otherrelated parties	Saleofgoods	27
	Saleofservices	•-
	Salary and perquisites (includes sitting fees)	14
	Health services availed	2
	Investment in compulsorily converteable debentures	100
	Expenses incurredonbehalfofthe related party	2
	CSRExpenditure	78
	Other expenses	22
	Outstandingasattheperiod end:
	- Trade andotherreceivables	19
	- Trade andotherpayables	3

==> picture [77 x 76] intentionally omitted <==